Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis - Effects of pancreatic enzyme supplementation

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 5, 2011, Pages

  Kuo, Paul ^a,c   Stevens, Julie E ^a,c   Russo, Antonietta ^a,c   Maddox, Anne ^a,c   Wishart, Judith M ^a,c   Jones, Karen L ^a,c   Greville, Hugh ^b   Hetzel, David ^b   Chapman, Ian ^a,c   Horowitz, Michael ^a,c   Rayner, Christopher K ^a,b,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; KREON; PANCREAS ENZYME;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; ENZYME THERAPY; FEMALE; FOOD COMPOSITION; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HUMAN; MALE; OUTCOME ASSESSMENT; PANCREAS EXOCRINE INSUFFICIENCY; POTATO; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; TREATMENT RESPONSE;

ADULT; BLOOD GLUCOSE; CYSTIC FIBROSIS; DIETARY CARBOHYDRATES; DIETARY FATS; DOUBLE-BLIND METHOD; FEMALE; GASTRIC EMPTYING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; INCRETINS; INSULIN; LIPASE; MALE; PANCREAS; YOUNG ADULT;

SOLANUM TUBEROSUM;

EID: 79955674575     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2460     Document Type: Article

References (20)

1. Bismuth E, Laborde K, Taupin P, Velho G, Ribault V, Jennane F, Grasset E, Sermet I, de Blic J, Lenoir G, Robert JJ 2008 Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr 152:540-545, 545.e1
2. Yung B, Noormohamed FH, Kemp M, Hooper J, Lant AF, Hodson ME 2002 Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and β-cell dysfunction. Diabet Med 19:221-226 (Pubitemid 34429653)
3. Deacon CF 2005 What do we know about the secretion and degradation of incretin hormones? Regul Pept 128:117-124
4. Meier JJ, Nauck MA 2004 The potential role of glucagon-like peptide 1 in diabetes. Curr Opin Investig Drugs 5:402-410
5. Adrian TE, McKiernan J, Johnstone DI, Hiller EJ, Vyas H, Sarson DL, Bloom SR 1980 Hormonal abnormalities of the pancreas and gut in cystic fibrosis. Gastroenterology 79:460-465 (Pubitemid 10056391)
6. Ross SA, Morrison D, McArthurRG1981 Hypersecretion of gastric inhibitory polypeptide in nondiabetic children with cystic fibrosis. Pediatrics 67:252-254
7. Allen JM, Penketh AR, Adrian TE, Lee YC, Sarson DL, HodsonME, Batten JC, Bloom SR 1983 Adult cystic fibrosis: postprandial response of gut regulatory peptides. Gastroenterology 85:1379-1383 (Pubitemid 14232923)
8. Pilichiewicz AN, Chaikomin R, Brennan IM, Wishart JM, Rayner CK, Jones KL, Smout AJ, Horowitz M, Feinle-Bisset C 2007 Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. Am J Physiol Endocrinol Metab 293:E743-E753 (Pubitemid 47358986)
9. Pilichiewicz A, O'Donovan D, Feinle C, Lei Y, Wishart JM, Bryant L, Meyer JH, Horowitz M, Jones KL 2003 Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. J Clin Endocrinol Metab 88:3829-3834 (Pubitemid 37034535)
10. Baker SS, Borowitz D, Duffy L, Fitzpatrick L, Gyamfi J, Baker RD 2005 Pancreatic enzyme therapy and clinical outcomes in patients with cystic fibrosis. J Pediatr 146:189-193
11. Kalnins D, Corey M, Ellis L, Durie PR, Pencharz PB 2005 Combining unprotected pancreatic enzymes with pH-sensitive entericcoated microspheres does not improve nutrient digestion in patients with cystic fibrosis. J Pediatr 146:489-493 (Pubitemid 40469711)
12. Carney BI, Jones KL, Horowitz M, Sun WM, Penagini R, Meyer JH 1995 Gastric emptying of oil and aqueous meal components in pancreatic insufficiency: effects of posture and on appetite.AmJ Physiol 268:G925-G932
13. Kuo P, Wishart JM, Bellon M, Smout AJ, Holloway RH, Fraser RJ, Horowitz M, Jones KL, Rayner CK 2010 Effects of physiological hyperglycemia on duodenal motility and flow events, glucose absorption, and incretin secretion in healthy humans. J Clin Endocrinol Metab 95:3893-3900
14. Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE, Nauck MA 2003 Gastric inhibitory polypeptide (GIP) dosedependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46:798-801 (Pubitemid 36831408)
15. Knop FK, Vilsbøll T, Larsen S, Højberg PV, Vølund A, Madsbad S, Holst JJ, Krarup T 2007 Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J Physiol Endocrinol Metab 292:E324-E330 (Pubitemid 46052957)
16. Meyer JH, Lake R 1997 Mismatch of duodenal deliveries of dietary fat and pancreatin from enterically coated microspheres. Pancreas 15:226-235 (Pubitemid 27524671)
17. Taylor CJ, Hillel PG, Ghosal S, Frier M, Senior S, Tindale WB, Read N1999 Gastric emptying and intestinal transit of pancreatic enzyme supplements in cystic fibrosis. Arch Dis Child 80:149-152
18. De Boeck K, Delbeke I, Eggermont E, Veereman-Wauters G, Ghoos Y 1998 Lipid digestion in cystic fibrosis: comparison of conventional and high-lipase enzyme therapy using the mixed-triglyceride breath test. J Pediatr Gastroenterol Nutr 26:408-411 (Pubitemid 28160689)
19. Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK 1994 The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 51:63-74 (Pubitemid 24119981)
20. Rosenecker J, Eichler I, Bärmeier H, von der HardtH2001 Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents. Pediatr Pulmonol 32:351-355